vitamin a
Approved
Jul 28, 1947
Retonol, also known as Vitamin A1, is a vitamin found in food and used as a dietary supplement. It is used to treat and prevent vitamin A deficiency. It is also used to prevent further issues in those who have measles. Retinol is used as a metabolic precursor of retinoic acid to treat skin-related conditions, such as cellulite, skin aging, photodamage. — NCATS
Clinical trial activity
154 trials · 191 clinical orgs · 26 marketing orgs
Earliest trial started May 1, 1984 (NCT00000114)
Timeline
1940s
- Jul 28, 1947
Roche — Earliest FDA Approval
- Jul 28, 1947
Roche — Marketing Organization
- Jul 28, 1947
Roche — NDA Secondary Org
- Jul 28, 1947
Roche — NDA Organization
- May 18, 1949
Casper Pharma LLC — NDA Secondary Org
1970s
- Nov 17, 1972
Sterling-Winthrop — Marketing Organization
- Dec 19, 1972
Teva — Marketing Organization
- Mar 14, 1973
Bayer — Marketing Organization
- May 2, 1973
MK Labs — Marketing Organization
- May 4, 1973
West-Ward Pharmaceutical — Marketing Organization
- Jul 13, 1973
Impax Laboratories — Marketing Organization
- Jul 18, 1973
Eli Lilly — Marketing Organization
- Nov 13, 1973
University of Pennsylvania — Marketing Organization
- Mar 6, 1974
Belmar Pharmacy — Marketing Organization
- Jun 10, 1974
Banner Pharmacaps — Marketing Organization
1980s
- Nov 6, 1981
Abraxis — Marketing Organization
- Nov 6, 1981
Abraxis — NDA Secondary Org
- Jul 13, 1982
Watson Pharmaceuticals — Marketing Organization
- Jul 13, 1982
Watson Pharmaceuticals — NDA Secondary Org
- Jan 1, 1984
Earliest Phase 3 Sponsor(trial)
2000s
2020s
- Apr 9, 2026
Apotex — Marketing Organization
Indications
Studied for
- Anemia · Phase 4
- Anemia, Iron-Deficiency · Phase 3
- Asthma · Phase 2
- Atherosclerosis · Phase 4
- Attention Deficit Disorder with Hyperactivity · Phase 4
- Bronchopulmonary Dysplasia · Phase 1/Phase 2
- Burns · Phase 1
- Carcinoma, Non-Small-Cell Lung · Early Phase 1
- Central Serous Chorioretinopathy · Phase 2
- Cognitive Dysfunction · Phase 2
- Colorectal Neoplasms · Phase 2
- Communicable Diseases · Phase 3
- COVID-19 · Phase 2
- Cytochrome P-450 CYP2D6 · Phase 1
- Dark Adaptation · Phase 2
- Dermatology · Phase 4
- Diabetes Mellitus · Phase 2/Phase 3
- Diabetes Mellitus, Type 2 · Phase 4
- Diabetic Foot · Phase 2/Phase 3
- Diarrhea · Phase 4
- Dry Eye Syndromes · Phase 4
- Enterocolitis, Necrotizing · Phase 3
- Eye Diseases · Early Phase 1
- Graft vs Host Disease · Phase 2
- Growth and Development · Phase 3
- Healthy Volunteers · Phase 2
- Helminthiasis · Phase 4
- HIV · Phase 2
- HIV Infections · Phase 3
- HIV Seronegativity · Phase 2
- Infant, Low Birth Weight · Phase 1/Phase 2
- Infant Mortality · Phase 4
- Infant, Newborn · Phase 3
- Infant, Premature · Phase 1/Phase 2
- Infant, Small for Gestational Age · Phase 1/Phase 2
- Infections · Phase 2
- Infectious Disease Transmission, Vertical · Phase 3
- Influenza A Virus, H1N1 Subtype · Phase 4
- Iron Deficiencies · Phase 3
- Kidney Calculi · Phase 4
- Kidney Transplantation · Early Phase 1
- Leukemia, Biphenotypic, Acute · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Lung Neoplasms · Phase 4
- Lymphoma, Non-Hodgkin · Phase 2
- Macular Degeneration · Early Phase 1
- Malaria · Phase 3
- Malaria Vaccines · Phase 3
- Malnutrition · Phase 3
- Maternal Health · Phase 3
- Maternal Mortality · Phase 3
- Meningitis · Phase 3
- Morbidity · Phase 3
- Mortality · Phase 4
- Multiple Sclerosis, Relapsing-Remitting · Phase 4
- Mycobacterium tuberculosis · Phase 3
- Myelodysplastic Syndromes · Phase 2
- Neoplasm Metastasis · Phase 2
- Neoplasms · Phase 1
- Non-alcoholic Fatty Liver Disease · Early Phase 1
- Obesity · Phase 4
- Optic Atrophy, Hereditary, Leber · Phase 1
- Ovarian Neoplasms · Phase 1/Phase 2
- Pediatrics · Phase 4
- Pneumonia · Phase 4
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Premature Birth · Phase 4
- Purpura · Phase 4
- Purpura, Thrombocytopenic, Idiopathic · Phase 2/Phase 3
- Respiration, Artificial · Phase 1/Phase 2
- Respiratory Distress Syndrome, Newborn · Phase 3
- Respiratory Tract Infections · Phase 4
- Retinitis Pigmentosa · Phase 3
- Retinopathy of Prematurity · Phase 4
- Rhytidoplasty · Phase 2
- Sepsis · Phase 4
- Skin Aging · Phase 4
- Skin Care · Early Phase 1
- Skin Diseases · Phase 2
- Skin Neoplasms · Early Phase 1
- Surface-Active Agents · Phase 3
- Vitamin A · Phase 3
- Vitamin A Deficiency · Phase 3
- Vitamin D Deficiency · Phase 2
- Vitamins · Phase 2/Phase 3
- Wet Macular Degeneration · Early Phase 1
- Zinc · Phase 3
Mechanism of action
Combination products
berocca pn
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, biotin, panthenol, pyridoxine, riboflavin, ergocalciferol
Also known as m.v.c, mvc plus
infuvite
with vitamin d3, vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, vitamin k, biotin, panthenol, pyridoxine, riboflavin
Also known as infuvite pediatric, infuvite pediatric (pharmacy bulk package)
m.v.i. adult (pharmacy bulk package)
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, vitamin k, biotin, panthenol, pyridoxine, riboflavin, ergocalciferol
m.v.i. pediatric
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, biotin, panthenol, pyridoxine, riboflavin, phytonadione, ergocalciferol
vitape
with vitamin e, folic acid, cyanocobalamin, vitamin c, nicotinamide, thiamine, pantothenic acid, biotin, pyridoxine, riboflavin, phytonadione, ergocalciferol
Approval history
- approvedJul 28, 1947
Chemistry & pharmacology
SMILES
CCCCCCCCCCCCCCCC(=O)OC/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C- Mol. weight
- 524.87 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral, Parenteral
- Availability
- Prescription Only
Oral
Yes
Parenteral
Yes
Topical
No
Sources
- WikipediaVitamin A ↗
- NCATS81G40H8B0T ↗
- ChEMBLCHEMBL986 ↗
- ChEMBLCHEMBL486193 ↗
- ChEMBLCHEMBL1675 ↗
Also known as
- (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
- (2e,4e,6e,8e)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
- 9-cis-retinyl acetate
- 9-cis-retinyl acetate
- afaxin
- afaxin
- all-trans-retinol
- all-trans-retinol
- all-trans-retinyl acetate
- all-trans-retinyl alcohol
- all-trans-retinyl alcohol
- all-trans-vitamin a alcohol
- all-trans-vitamin a alcohol
- alphalin
- alphalin
- aquasol a
- aquasol a
- arovit
- arovit
- chocola a
- dagravit a forte
- del-vi-a
- del-vi-a
- dif vitamin a masivo
- nepalm
- oleovitamin a
- oleovitamin a
- qlt091001
- qlt091001
- qlt091001
- qlt091001
- retinit
- retinol
- retinol
- retinol
- retinol
- retinol
- retinol
- retinol acetate
- retinol acetate
- retinol acetate
- retinol acetate
- retinol acetate
- retinol acetate, (9,13-cis)-isomer
- retinol, hexadecanoate
- retinol palmitate
- retinol palmitate
- retinol palmitate
- retinol palmitate
- retinol (vit a)
- retinol (vit a)
- retinol (vit a)
- retinyl acetate
- retinyl acetate
- retinyl acetate
- retinyl acetate
- retinyl acetate
- retinyl palmitate
- retinyl palmitate
- retinyl palmitate
- retinyl palmitate
- ro-a-vit
- ro-a-vit
- vi-dom-a
- vi-dom-a
- vitamin a
- vitamin a
- vitamin a
- vitamin a
- vitamin a
- vitamin a
- vitamin a
- vitamin a
- vitamin a1
- vitamin a1
- vitamin a1
- vitamin a1
- vitamin a1
- vitamin a1
- vitamin a 1
- vitamin a acetate
- vitamin a acetate
- vitamin a dispersa
- vitamin a oil
- vitamin a oil
- vitamin a palmitate
- vitamin a palmitate
- vitamin a palmitate
- vitamin a palmitate
- vitamin a palmitate
- vitamin a palmitate
- vitamin a palmitate
- vitamin a palmitate
- vitamin-a-saar
- vitamin a solubilized
- vitamin a solubilized
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06450925 | Phase 2 | Nov 30, 2024 | University of Cincinnati |
| NCT06623227 | N/A | Sep 28, 2024 | University of Hasanuddin, University of Indonesia, University of Modena and Reggio Emilia |
| NCT06508099 | Phase 2 | May 15, 2024 | Pavlov First Saint Petersburg State Medical University |
| NCT06257680 | Phase 1 | Apr 8, 2024 | Aeonvital Biomedicine |
| NCT06105060 | Early Phase 1 (Phase 1) | Dec 17, 2023 | Beni Suef University |
| NCT05774964 | Phase 2 | Mar 15, 2023 | Dalian Medical University |
| NCT05720559 | Phase 2 | Mar 1, 2023 | Dalian Medical University |
| NCT05702398 | Early Phase 1 (Phase 1) | Mar 1, 2023 | Rhode Island Hospital |
| NCT05285293 | N/A | Jun 1, 2022 | Cairo University |
| NCT05045703 | N/A | Jan 31, 2022 | Duke University, Foundation Fighting Blindness |
| NCT05271045 | N/A | Dec 1, 2021 | National Nutrition and Food Technology Institute |
| NCT05039476 | N/A | Sep 1, 2021 | Chemist Confessions, Inc., Citruslabs |
| NCT04920760 | Phase 2 | Jun 21, 2021 | Shiraz University |
| NCT06677684 | N/A | Feb 1, 2021 | Hormozgan University of Medical Sciences |
| NCT04884516 | N/A | Jan 19, 2021 | Citruslabs, Embody Beauty, Inc. |
| NCT04563429 | N/A | Oct 1, 2020 | Tel Aviv University |
| NCT04238845 | N/A | Jul 31, 2020 | Institut et Haute école de la Santé, La Source |
| NCT04900415 | Phase 2 | Jul 22, 2020 | The University of Hong Kong |
| NCT04499820 | N/A | Jun 26, 2020 | Centre Hospitalier Intercommunal Creteil, Laboratoires Thea |
| NCT04284059 | Phase 4 | May 30, 2020 | Chongqing Medical University |
Organizations
Research & Development (191)
Marketing (32)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ARCUM | For profit | MKTG | — |
| Abraxis | For profit | MKTG | Nov 6, 1981 |
| Abraxis | For profit | NDA2 | Nov 6, 1981 |
| Apotex | For profit | MKTG | Apr 9, 2026 |
| AstraZeneca | For profit | MKTG | — |
| Banner Pharmacaps | For profit | MKTG | Jun 10, 1974 |
| Bayer | For profit | MKTG | Mar 14, 1973 |
| Belmar Pharmacy | For profit | MKTG | Mar 6, 1974 |
| Bristol-Myers Squibb | For profit | MKTG | — |
| Casper Pharma LLC | For profit | NDA2 | May 18, 1949 |
| Chase Pharmaceuticals Corporation | For profit | MKTG | — |
| DEL RAY LABS | For profit | MKTG | — |
| Eli Lilly | For profit | MKTG | Jul 18, 1973 |
| Elkins Sinn | For profit | MKTG | — |
| Everylife Foundation for Rare Diseases | Academic/Hospital | MKTG | — |
| Hospira | For profit | MKTG | Feb 20, 1953 |
| Hospira | For profit | NDA2 | Feb 20, 1953 |
| Impax Laboratories | For profit | MKTG | Jul 13, 1973 |
| MK Labs | For profit | MKTG | May 2, 1973 |
| Novartis | For profit | NDA2 | May 18, 2000 |
| Roche | For profit | MKTG | Jul 28, 1947 |
| Roche | For profit | NDA2 | Jul 28, 1947 |
| Roche | For profit | NDA | Jul 28, 1947 |
| Sandoz | For profit | MKTG | May 18, 2000 |
| Sandoz | For profit | NDA2 | May 18, 2000 |
| Sterling-Winthrop | For profit | MKTG | Nov 17, 1972 |
| Teligent Pharmaceuticals | For profit | NDA2 | — |
| Teva | For profit | MKTG | Dec 19, 1972 |
| University of Pennsylvania | Academic/Hospital | MKTG | Nov 13, 1973 |
| Watson Pharmaceuticals | For profit | MKTG | Jul 13, 1982 |
| Watson Pharmaceuticals | For profit | NDA2 | Jul 13, 1982 |
| West-Ward Pharmaceutical | For profit | MKTG | May 4, 1973 |